|
in welchem verhältnis steht dieser bio-chip eigtl zu nbx`s mini-lab? Press Release Source: Affymetrix, Inc. New Affymetrix GeneChip(R) Scanner Analyzes Up to Five Times More Data Monday June 13, 8:00 am ET SANTA CLARA, Calif., June 13 /PRNewswire-FirstCall/ -- Affymetrix Inc. (Nasdaq: AFFX - News) today announced the launch of the GeneChip® Scanner (GCS) 3000 7G, which enables analysis of microarrays that feature 500 percent more data than previous generations. With the ability to scan smaller features, ranging in size from 2.5 um to 0.51um, the GCS 3000 7G supports the latest high-density GeneChip microarrays for tiling, all-exon and single nucleotide polymorphism (SNP) genotyping research. The GCS 3000 7G is designed to provide peak scanning performance for all applications including RNA expression and DNA analysis. Compatible with data from previous experiments using GeneChip microarrays, as well as with other Affymetrix instruments and software, the GCS 3000 7G provides a seamless transition for customers. "The GeneChip Scanner 3000 7G combines advanced design improvements with high-resolution scanning to dramatically improve efficiency in genetic analysis for gene expression and DNA analysis applications," said Chip Leveille, Vice President of Product Technologies Group, Affymetrix. "We designed the original GCS 3000 to be forward-compatible, requiring only a simple upgrade to support the next-generation of high-density microarrays that develop as GeneChip technology continues to advance." Specific features of the GCS 3000 7G include: -- A scanning resolution that has been extended down to submicron pixelation of 0.51um, enabling scanning of next-generation high-density GeneChip microarrays. -- A new powerful dual processor workstation and software updates for processing and analyzing up to five times as much data per experiment. -- An improved autofocus algorithm for scanning standard-sized 49-format microarrays 30 percent faster than the original GCS 3000. -- An innovative, patented scanning system called the Flying Objective(TM) provides superb image uniformity and accuracy. -- A simple, high-numerical aperture optical architecture provides consistent excitation and emission paths over the entire scan field. The new scanner is also included as part of the GCS 3000 MegAllele(TM) System. Available as both a complete system and an upgrade to existing systems, the GCS 3000 MegAllele System features a four-color scanning capability that supports the highly multiplexed assay technology that was co-developed by Affymetrix and ParAllele BioScience. About Affymetrix: Affymetrix scientists invented the world`s first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip® technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world`s top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,200 systems have been shipped around the world and more than 3,000 peer-reviewed papers have been published using the technology. Affymetrix` patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyze the relationship between genetics and health. Headquartered in Santa Clara, Calif., Affymetrix has subsidiaries in Europe and Asia in addition to manufacturing facilities in Sacramento, Calif. and Bedford, Mass. The company has about 900 employees worldwide. For more information about Affymetrix, please visit the company`s website at www.Affymetrix.com. All statements in this press release that are not historical are "forward- looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix` "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to risks of the Company`s ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses, uncertainties relating to technological approaches, manufacturing, product development (including uncertainties relating to commercial and technological success of the GeneChip Scanner 3000 7G discussed in this press release), personnel retention, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix` Form 10-K for the year ended December 31, 2004 and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in Affymetrix` expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc. |
|
| aus der Diskussion: | November ag - Wann gehts endlich bergauf |
| Autor (Datum des Eintrages): | amorphis (15.06.05 16:09:03) |
| Beitrag: | 7,530 von 19,813 (ID:16896431) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |